Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Citi
Daiichi Sankyo
Johnson and Johnson
Covington
AstraZeneca
Harvard Business School
Chubb

Generated: June 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,900,175

« Back to Dashboard

Summary for Patent: 6,900,175
Title: Methods of administering dalbavancin for treatment of bacterial infections
Abstract:The invention provides methods and compositions for treatment of bacterial infections. Methods of the invention include administration of dalbavancin for treatment of a bacterial infection, in particular a Gram-positive bacterial infection of skin and soft tissue. Dosing regimes include once weekly administration of dalbavancin, which often remains at therapeutic levels in the bloodstream for at least one week, providing prolonged therapeutic action against a bacterial infection.
Inventor(s): Cavaleri; Marco (Saronno, IT), Jabes; Daniela (Cassina Rizzardi, IT), Henkel; Timothy (Berwyn, PA), Malabarba; Adriano (Buccinasco, IT), Mosconi; Giorgio (Malvern, PA), Stogniew; Martin (Blue Bell, PA), White; Richard J. (Emeryville, CA)
Assignee: Vicuron Pharmaceuticals Inc. (King of Prussia, PA)
Application Number:10/714,261
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,900,175

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc DALVANCE dalbavancin hydrochloride POWDER;IV (INFUSION) 021883-001 May 23, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN. ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,900,175

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,115,564 Stable pharmaceutical compositions of dalbavancin and methods of administration ➤ Sign Up
8,143,212 Dalbavancin compositions for treatment of bacterial infections ➤ Sign Up
7,119,061 Dalbavancin compositions for treatment of bacterial infections ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cantor Fitzgerald
Harvard Business School
Cipla
Merck
UBS
Fish and Richardson
Chubb
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.